Administration of the anti‐endoglin antibody TRC 105 as a single agent was reported associated with a reduction in PSA levels in eight (40%) of 20 patients with metastatic castration‐resistant prostate cancer 22, and with one (9.1%) partial response among 11 patients with advanced HCC and disease progression following prior sorafenib therapy 23. Here, ENG is linked to hepatocellular carcinoma.